In older adults with diabetes, GLP-1 receptor agonists were tied to a slightly lower risk for depression compared with one ...

Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

The global Heart Failure Drugs Market is valued at $8.6 billion in 2024 and is projected to reach a value of $21.4 billion by 2035. This growth represents a Compound Annual Growth Rate (CAGR) of 12.1% ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...

Overview of the Migraine Drugs MarketThe global Migraine Drugs Market is valued at $6.37 billion in 2024 and is projected to ...

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It ...

Acting in the right place at the right time is the key to effective medical treatment with minimal side effects. However, this feat remains difficult to achieve. Biologists and chemists have now ...

A recently approved drug has shown promise in reducing heart attacks and strokes in patients with type 2 diabetes and kidney disease. This medication, a sodium-glucose cotransporter (SGLT) inhibitor, ...

The FDA has accepted a priority review of a new biannual HIV prevention injection, with a decision expected by June 19, 2025.

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be ...